Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

New Technology Generates Cancer Killing Antibody Drug Conjugates

By BiotechDaily International staff writers
Posted on 11 Mar 2014
Image: In order to overcome the known limitations inherent to chemical conjugation of small molecule toxic drugs to antibodies, NBE-Therapeutics has developed a patent-pending technology for the specific enzymatic conjugation of drugs to antibodies (Photo courtesy of NBE-Therapeutics).
Image: In order to overcome the known limitations inherent to chemical conjugation of small molecule toxic drugs to antibodies, NBE-Therapeutics has developed a patent-pending technology for the specific enzymatic conjugation of drugs to antibodies (Photo courtesy of NBE-Therapeutics).
A novel technology for generation of specific toxin-bearing antibodies for treatment of cancer has been validated in a recent series of proof-of-concept studies.

NBE-Therapeutics (Basel, Switzerland) presented evidence of the successful validation of its enzymatic SMAC-Technology for the generation of potent next-generation antibody drug conjugates (ADCs) at the international World ADC summit held in Frankfurt (Germany).

NBE-Therapeutics' patent-pending SMAC (sortase-mediated antibody conjugation)-Technology utilizes highly selective sortase enzymes for site-specific and efficient conjugation of toxic payloads to therapeutic antibodies. Sortases are a group of prokaryotic enzymes that modify surface proteins by recognizing and cleaving a carboxyl-terminal sorting signal. For most substrates of sortase enzymes, the recognition signal consists of the motif LPXTG (leucine-proline-any amino acid-threonine-glycine), then a highly hydrophobic transmembrane sequence, then a cluster of basic residues such as arginine. Cleavage occurs between the threonine and glycine. Sortases occur in almost all gram-positive bacteria and the occasional gram-negative.

ADCs represent a new type of targeted therapy, in which highly potent cellular toxins (toxic payloads) are conjugated to cancer-specific antibodies allowing the targeted destruction of cancer cells without affecting healthy cells or tissue.

In proof-of-concept studies, it was demonstrated that SMAC-generated ADCs displayed the same potencies in cancer cell killing experiments as commercially available benchmark ADCs composed of identical antibody and toxin, even when significantly smaller amount of toxic payload was conjugated.

The company is now planning to leverage its SMAC-Technology for the development of a preclinical and clinical pipeline of next-generation ADC products, aimed at providing improved targeted therapies for difficult to treat cancers.

Related Links:

NBE-Therapeutics 



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.